Unilever is facing a growing investor backlash against its £50bn bid for the consumer health unit of GSK, as its share price tumbled to its lowest level in nearly five years.
联合利华(Unilever)以500亿英镑收购葛兰素史克(GSK)消费者健康部门的交易，正面临越来越多的投资者反弹，该公司股价跌至近5年来的最低水平。
您已阅读4%（249字），剩余96%（5514字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。